MX350046B - Tratamientos para trastornos gastrointestinales. - Google Patents

Tratamientos para trastornos gastrointestinales.

Info

Publication number
MX350046B
MX350046B MX2014016035A MX2014016035A MX350046B MX 350046 B MX350046 B MX 350046B MX 2014016035 A MX2014016035 A MX 2014016035A MX 2014016035 A MX2014016035 A MX 2014016035A MX 350046 B MX350046 B MX 350046B
Authority
MX
Mexico
Prior art keywords
gastrointestinal disorders
treatments
present
pharmaceutical compositions
peptides
Prior art date
Application number
MX2014016035A
Other languages
English (en)
Inventor
Kessler Marco
Fretzen Angelika
G Currie Mark
P Zimmer Daniel
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350046(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of MX350046B publication Critical patent/MX350046B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)

Abstract

La presente invención se refiere a péptidos que son útiles para el tratamiento de trastornos gastrointestinales. La presente invención también proporciona composiciones y métodos para tratar trastornos gastrointestinales y composiciones farmacéuticas para lograr lo mismo. En algunas modalidades, estas composiciones farmacéuticas incluyen formas de dosis orales.
MX2014016035A 2009-11-09 2010-11-09 Tratamientos para trastornos gastrointestinales. MX350046B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25926409P 2009-11-09 2009-11-09
PCT/US2010/056042 WO2011057272A1 (en) 2009-11-09 2010-11-09 Treatments for gastrointestinal disorders

Publications (1)

Publication Number Publication Date
MX350046B true MX350046B (es) 2017-08-24

Family

ID=43503086

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014016035A MX350046B (es) 2009-11-09 2010-11-09 Tratamientos para trastornos gastrointestinales.
MX2012005368A MX2012005368A (es) 2009-11-09 2010-11-09 Tratamientos para transtornos gastrointestinales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012005368A MX2012005368A (es) 2009-11-09 2010-11-09 Tratamientos para transtornos gastrointestinales.

Country Status (26)

Country Link
US (3) US8507447B2 (es)
EP (1) EP2499154B1 (es)
JP (1) JP5913115B2 (es)
KR (1) KR20120115495A (es)
CN (1) CN102812038B (es)
AR (1) AR078950A1 (es)
AU (1) AU2010314866B2 (es)
BR (1) BR112012011730A2 (es)
CA (1) CA2779482A1 (es)
CL (1) CL2012001186A1 (es)
CO (1) CO6551683A2 (es)
CR (1) CR20120303A (es)
EA (1) EA022817B1 (es)
EC (1) ECSP12011962A (es)
ES (1) ES2620153T3 (es)
GE (1) GEP20166435B (es)
IL (1) IL219596A0 (es)
MX (2) MX350046B (es)
NZ (1) NZ599751A (es)
PH (1) PH12012500916B1 (es)
SG (1) SG10201407403UA (es)
TW (1) TWI482626B (es)
UA (1) UA114274C2 (es)
UY (2) UY33017A (es)
WO (1) WO2011057272A1 (es)
ZA (1) ZA201203342B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP2012510518A (ja) * 2008-12-02 2012-05-10 アイロンウッド ファーマシューティカルズ，インコーポレーテッド 体液貯留障害を処置するための方法および組成物
US8507447B2 (en) 2009-11-09 2013-08-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
RU2012128509A (ru) * 2009-12-07 2014-01-20 Айронвуд Фармасьютикалз, Инк. Способы лечения заболеваний желудочно-кишечного тракта
CA2835624A1 (en) * 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US20160213739A1 (en) * 2011-05-11 2016-07-28 Ironwood Pharmaceuticals, Inc Treatments for disorders using guanylate cyclase c agonists
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP6312592B2 (ja) * 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
AU2014331812B2 (en) * 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2016015055A1 (en) * 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Colon cleansing compositions
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB290795A (en) 1927-04-08 1928-05-24 British Colour Printing Compan Improvements in or relating to advertising or display devices
ATE259648T1 (de) 1993-10-26 2004-03-15 Univ Jefferson Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
US5962220A (en) 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU2001256315A1 (en) * 2000-04-22 2001-11-07 Ipf Pharmaceuticals Gmbh Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR101227626B1 (ko) 2003-01-28 2013-02-01 아이언우드 파마슈티컬스, 인코포레이티드 위장병 치료 방법 및 위장병 치료용 조성물
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20090253634A1 (en) 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
MX354786B (es) * 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
MX385591B (es) 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
US8507447B2 (en) * 2009-11-09 2013-08-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US8748575B2 (en) 2010-06-09 2014-06-10 Combimab, Inc. Therapeutic peptides

Also Published As

Publication number Publication date
CR20120303A (es) 2012-08-08
AR078950A1 (es) 2011-12-14
ECSP12011962A (es) 2012-07-31
CO6551683A2 (es) 2012-10-31
EA201290322A1 (ru) 2013-01-30
JP2013510182A (ja) 2013-03-21
EP2499154A1 (en) 2012-09-19
TW201116291A (en) 2011-05-16
SG10201407403UA (en) 2014-12-30
UA114274C2 (uk) 2017-05-25
NZ599751A (en) 2014-08-29
US20110118184A1 (en) 2011-05-19
AU2010314866A1 (en) 2012-05-31
CA2779482A1 (en) 2011-05-12
GEP20166435B (en) 2016-02-25
US20130085107A1 (en) 2013-04-04
EP2499154B1 (en) 2016-12-21
CN102812038A (zh) 2012-12-05
PH12012500916A1 (en) 2018-01-29
TWI482626B (zh) 2015-05-01
CN102812038B (zh) 2016-05-18
CL2012001186A1 (es) 2013-07-12
KR20120115495A (ko) 2012-10-18
MX2012005368A (es) 2012-06-13
UY33017A (es) 2011-06-30
AU2010314866B2 (en) 2014-10-30
WO2011057272A1 (en) 2011-05-12
IL219596A0 (en) 2012-06-28
EA022817B1 (ru) 2016-03-31
PH12012500916B1 (en) 2018-03-23
US8946158B2 (en) 2015-02-03
US20140024593A1 (en) 2014-01-23
US8507447B2 (en) 2013-08-13
US20140179607A9 (en) 2014-06-26
UY33018A (es) 2011-01-31
JP5913115B2 (ja) 2016-05-11
ES2620153T3 (es) 2017-06-27
BR112012011730A2 (pt) 2016-03-08
ZA201203342B (en) 2013-01-30

Similar Documents

Publication Publication Date Title
MX350046B (es) Tratamientos para trastornos gastrointestinales.
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201290919A1 (ru) Индазольные соединения и их применение
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
CO6300826A2 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
EA201490254A1 (ru) Комбинированное лечение гепатита с
GT200600280A (es) Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201200428A1 (ru) Композиция и способ для лечения ожирения
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler